Sarepta Therapeutics Faces Securities Class Action Lawsuit

A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. (SRPT) on behalf of those who purchased or otherwise acquired Sarepta securities between June 22, 2023, and June 24, 2025. The lead plaintiff deadline is August 25, 2025. The complaint alleges that Sarepta made false and/or misleading statements about its gene therapy treatment, ELEVIDYS, which posed significant safety risks and had severe side effects.

Sarepta Therapeutics, Inc. (SRPT) is facing a securities class action lawsuit, with allegations that the company made false and misleading statements about its gene therapy treatment, ELEVIDYS. The lawsuit, filed on behalf of investors who purchased or otherwise acquired Sarepta securities between June 22, 2023, and June 24, 2025, alleges that the company failed to disclose significant safety risks and severe side effects associated with ELEVIDYS.

The complaint, filed by the law firm Kessler Topaz Meltzer & Check, LLP, states that Sarepta made false and/or misleading statements and/or failed to disclose that ELEVIDYS posed significant safety risks to patients, that trial regimes and protocols failed to detect severe side effects, and that the severity of adverse events would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals [1].

Investors who suffered losses due to these allegations are encouraged to contact the law firm for more information and to participate in the lawsuit. The lead plaintiff deadline is August 25, 2025 [1].

Meanwhile, Longeveron Inc. (LGVN), another biotechnology company, has received U.S. FDA approval for its IND application to conduct a Phase 2 pivotal registration clinical trial evaluating laromestrocel as a treatment for pediatric dilated cardiomyopathy (DCM). The acceptance of the IND application allows Longeveron to move directly to the Phase 2 trial, with initiation anticipated in the first half of 2026 [2].

References:

[1] https://www.prnewswire.com/news-releases/class-action-announcement-for-sarepta-therapeutics-inc-srpt-kessler-topaz-meltzer--check-llp-announces-that-a-securities-class-action-lawsuit-has-been-filed-against-sarepta-therapeutics-inc-302500470.html

[2] https://www.globenewswire.com/news-release/2025/07/08/3111851/0/en/Longeveron-Announces-U-S-FDA-Approval-of-IND-Application-for-a-Phase-2-Pivotal-Registration-Study-Evaluating-Laromestrocel-as-a-Treatment-of-Pediatric-Dilated-Cardiomyopathy-DCM.html